Compare Incyte Corporation (INCY) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ArcelorMittal SA — how do they compare? Incyte Corporation trades at $117.91 (market cap $23.11B), while ArcelorMittal SA trades at $66.16 (market cap $50.01B). The key difference: ArcelorMittal SA is far larger — about 2.2× Incyte Corporation's market cap, and ArcelorMittal SA pays a 0.91% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MT | |
|---|---|---|
Market Cap | $23.11B | $50.01B |
Sector | Health | Basic Materials |
52-Week High | $118.52 | $71.65 |
52-Week Low | $67.38 | $30.39 |
Enterprise Value | $19.13B | $59.33B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
ArcelorMittal (MT) trades at $65.81, down 0.96% on the day but remains near its 52-week high of $72.50. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent developments include a strategic AI collaboration with AWS and ongoing share buybacks, while analyst sentiment is mixed with 50% recommending Buy.
Outlook: MT presents value with attractive P/E (17.4) and P/B (0.91) ratios, supported by rising net margins. Risks include declining revenue trends, high capital expenditures, and exposure to steel market volatility. The stock's upside depends on execution of expansion projects and stable commodity pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
